|
rs121913237
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In all components (bilateral serous borderline tumors, low-grade serous carcinoma and mesonephric-like adenocarcinoma), an identical KRAS mutation was detected (NM_004985.4): c.35G>A, p.(G12D) proving a clonal association between the serous and mesonephric-like components and excluding a collision neoplasm.
|
30575604 |
2020 |
|
rs782212015
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found mutations encoding L640I and A643T in the B3 domain of human CEACAM5 in colorectal adenocarcinomas; structural studies indicated that these mutations would alter the interaction between CEACAM5 and TGFBR1.
|
31585122 |
2020 |
|
rs3746444
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Association of miRNA-499 rs3746444 A>G variants with adenocarcinoma of esophagogastric junction (AEG) risk and lymph node status.
|
31496728 |
2019 |
|
rs3765524
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, a significant association for rs3765524 with noncardia cancer (NCC) and adenocarcinoma which is predominant in China was also observed.
|
30931333 |
2019 |
|
rs7309332
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified by tumor histology, the association between the GLUT3 rs7309332C>T and OS/DFS was not limited to either squamous cell carcinoma (SCC) or adenocarcinoma (AC), although the significant association remained only in AC for OS (P = 0.40 for SCC and P = 0.04 for OS) and only in SCC for DFS (P = 0.03 for SCC and P = 0.08 for OS).
|
30954677 |
2019 |
|
rs766779326
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A total of three heterozygous missense ESR1 mutations, p.K303R (c.908A>G), p.T311M (c.932C>T) and p.Y537C (c.1610A>G), were identified in 3/207 (1.4%) cervical squamous cell carcinoma samples, which were absent in 27 adenosquamous carcinomas and 26 adenocarcinomas samples.
|
31452755 |
2019 |
|
rs779577244
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, an adenocarcinoma patient harboring concurrent <i>RET</i> fusion and <i>EGFR</i> L858R responded to combinatorial treatment of cabozantinib and osimertinib, with a progression-free survival of 5 months.
|
30131091 |
2019 |
|
rs1057519696
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
|
rs1057519816
|
|
|
0.010 |
GeneticVariation |
BEFREE |
HER2 S310Y single site substitution was discovered in recent years and afatinib efficacy for adenocarcinoma patients harboring S310Y mutation has not been reported.
|
29561699 |
2018 |
|
rs11134527
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the association analysis of these SNPs between adenocarcinoma and squamous cell carcinoma (SCC) showed that allele A of rs11134527 was associated with SCC (OR=0.65; 95% CI: 0.48-0.88).
|
29692628 |
2018 |
|
rs121913355
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
|
rs2073664
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Adenocarcinoma (ADCC) patients carrying the heterozygous (CT) genotype for DKK4 rs2073664 showed a better OS compared with wild genotype (log rank p = 0.01).
|
30346805 |
2018 |
|
rs217727
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs217727 SNP in lncRNA H19 was significantly associated with susceptibility to LC, particularly in squamous cell carcinoma and adenocarcinoma, and identified the homozygous A/A genotype as a risk factor for LC.
|
30071841 |
2018 |
|
rs2279574
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals are carrying DUSP6 rs2279574 AA and AC genotypes associated with an increased risk in developing lung squamous carcinoma in Han Chinese and with advanced NSCLC stages.
|
29578153 |
2018 |
|
rs2910164
|
|
|
0.010 |
GeneticVariation |
BEFREE |
miRNA-146a rs2910164 C>G polymorphism increased the risk of esophagogastric junction adenocarcinoma: a case-control study involving 2,740 participants.
|
29983589 |
2018 |
|
rs736775
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PF-based chemotherapy significantly decreased risk of death for patients carrying GPx3 rs736775 TC/CC and age ≤ 60 years or with diffused type adenocarcinoma compared to surgery alone.
|
30114685 |
2018 |
|
rs755683317
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
|
rs765660823
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The Q808H variation in the DDR2 gene was detected in one SCC sample, while no variant was seen in the ADC and LCC subtypes.
|
30048458 |
2018 |
|
rs11568820
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we conducted a hospital-based case-control study to examine the correlation of single nucleotide polymorphisms of VDR rs2107301T>C, rs2228570C>T, rs1989969C>T and rs11568820 G>A and gastric cardiac adenocarcinoma susceptibility.
|
28489590 |
2017 |
|
rs121913465
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation.
|
28024692 |
2017 |
|
rs12203582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the subgroup analysis, people carrying homozygous variants of rs2275913 and rs12203582 were more likely to develop lung cancer both in adenocarcinoma (OR: 2.33, 95% confidence interval = 1.34-4.05; OR: 1.84, 95% confidence interval = 1.04-3.25) and advanced (OR: 2.35, 95% confidence interval = 1.46-3.80; OR: 1.74, 95% confidence interval = 1.06-2.87) groups.
|
26073462 |
2017 |
|
rs1347093
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results indicated that rs1347093, rs1397529 polymorphisms were associated with lung cancer risk, especially with adenocarcinoma risk.
|
29212272 |
2017 |
|
rs1397529
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results indicated that rs1347093, rs1397529 polymorphisms were associated with lung cancer risk, especially with adenocarcinoma risk.
|
29212272 |
2017 |
|
rs150423237
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An adenocarcinoma patient with JM R675Q had erlotinib, 150 mg daily, added following progression of disease on carboplatin and paclitaxel and had a partial response for 4 months.
|
28573640 |
2017 |
|
rs1799724
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, subtype-specific associations were observed for gastric cardia adenocarcinomas at MUC1/TRIM46/1q22 rs2070803 [HRAA versus GA+GG = 2.16; 95% confidence interval (CI) = 1.24-3.78; P = 0.0068] and LTA/TNF/6p21.33 rs1799724 (HRTT+CT versus CC = 1.30; 95% CI = 1.07-1.57; P = 0.0077), and for diffuse-type GC at PSCA/8q24.3 rs2294008 (HRTT versus CT+CC = 1.99; 95% CI = 1.33-2.97; P = 7.8E-04).
|
29028942 |
2017 |